Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | FDPS | P14324 | 15/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298865 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9FDPS | |
| SCHEMBL3225341 | 0.98 | CA12 (0.46) | CA12CA1CA2CA9FDPS | |
| SCHEMBL6222263 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9FDPS | |
| SCHEMBL9615006 | 0.96 | FDPS (0.45) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161694 | 0.88 | FDPS (0.40) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161709 | 0.88 | FDPS (0.40) | CA12CA1CA2CA9FDPS | |
| SCHEMBL3067217 | 0.87 | CA12 (0.41) | CA12CA1CA2CA9FDPS | |
| SCHEMBL9082973 | 0.86 | FDPS (0.47) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161706 | 0.85 | FDPS (0.44) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161689 | 0.85 | FDPS (0.44) | CA12CA1CA2CA9FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140356423-A1 | FORMULATIONS OF LYCOPENE IN COMBINATION WITH BISPHOSPHONATES BONE RESORPTION INHIBITORS | ANGRES ISAAC A (US) | 2014-12-04 | — | — | US | claimed |
| US-20100055159-A1 | PERCUTANEOUS PREPARATIONS | TSUJI YASUHIRO | 2010-03-04 | — | — | US | claimed |
| EP-1434786-A4 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080207565-A1 | USE OF BISPHOSPHONATES FOR PAIN TREATMENT | NOVARTIS PHARMACEUTICALS CORPORATION | 2008-08-28 | — | — | US | claimed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1689744-A1 | ANTIRESORPTIVE MUTUAL SALT OF RALOXIFENE AND BISPHOSPHONIC ACID | Hanmi Pharm. Co., Ltd. (KR) | 2006-08-16 | — | — | EP | claimed |
| US-7090496-B2 | Endosseous implant | UNIVERSITE DE GENEVE (CH) | 2006-08-15 | — | — | US | claimed |
| US-20060166937-A1 | Bisphosphonates for the treatment of atherosclerosis and device comprising them | PRESCOTT MARGARET F | 2006-07-27 | — | — | US | claimed |
| EP-1351722-B1 | ENDOSSEOUS IMPLANT | UNIV GENEVE (CH) | 2006-07-05 | — | — | EP | claimed |
| EP-0573604-B1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1995-03-15 | — | — | EP | claimed |
| US-5366965-A | Administering polyphosphonate | BOEHRINGER MANNHEIM GMBH (DE) | 1994-11-22 | — | — | US | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| EP-0409881-B1 | N-HETEROCYCLIC PROPYLIDENE-1,1-BISPHOSPHONIC ACIDS, THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1993-02-10 | — | — | EP | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| US-5130304-A | Drugs for calcium metabolism for treatment of osteoporosis or arthritis | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-07-14 | — | — | US | claimed |
| EP-0409881-A1 | N-HETEROCYCLIC PROPYLIDENE-1,1-BISPHOSPHONIC ACIDS, THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION. | LEO PHARM PROD LTD (DK) | 1991-01-30 | — | — | EP | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| WO-1989009775-A1 | N-HETEROCYCLIC PROPYLIDENE-1,1-BISPHOSPHONIC ACIDS, THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1989-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207565-A1 | USE OF BISPHOSPHONATES FOR PAIN TREATMENT | SOST, OPRL1, BPGM | CA12 1036/4885CA1 374/4885CA2 495/4885 |
| US-20060166937-A1 | Bisphosphonates for the treatment of atherosclerosis and device comprising them | SOST, PTH1R, CASR | CA12 371/4885CA1 174/4885CA2 261/4885 |
| US-20100055159-A1 | PERCUTANEOUS PREPARATIONS | FFAR1, FFAR2, PPARD | CA12 2137/4885CA1 3883/4885CA2 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.